Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Business Insider

The CEO of a $1.6 billion biotech says his bet on AI is paying off with faster, cheaper research that could reshape the industry

Recursion is hosting about 60 investors and analysts at its headquarters in Utah. It has generated tons of data with AI and robots, aiming to find a better way to make drugs. Recursion, which has four ...
Forbes

Recursion Announces New Generative AI Platform To Speed Up Drug Discovery

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
Seeking Alpha

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...